Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Blood (2024) 144 (20): 2121–2135.

https://doi.org/10.1182/blood.2024024590

Published: 2024

Includes: Supplemental data

Journal Articles

Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis

Blood (2023) 142 (19): 1633–1646.

https://doi.org/10.1182/blood.2023019758

Published: 2023

Includes: Supplemental data

Journal Articles

Functional Characterization of GPRC5D alteration and Its Impact on Talquetamab Resistance in Relapsed/ Refractory Multiple Myeloma

Seungbin Han, Umair Munawar, Larissa Haertle, Cornelia Vogt, Silvia Nerreter, Eva Teufel, Xiang Zhou, Max Steinhardt, Florian Eisele, Peter Raab, Marietta Truger, Sara Dorado, Santiago Barrio, Claudia Haferlach, Joaquin Martínez-López, Hermann Einsele, Leo Rasche, Johannes M Waldschmidt, K. Martin Kortüm

Blood (2023) 142 (Supplement 1): 3323.

https://doi.org/10.1182/blood-2023-181607

Published: 2023

Journal Articles

Functional Imaging As a Key Diagnostic Tool in the Follow-up of RRMM Patients after CAR-T-Cell Therapy

Sven Schimanski, Hannah Hornburger, Sofie-Katrin Kadel, Anna Marie Ruckdeschel, Florian Eisele, Daniela Schneider, Anke Heidemeier, Andreas Buck, Rudolf Werner, Johannes M Waldschmidt, Paula Tabares, Andreas Beilhack, Johannes Duell, Hermann Einsele, K. Martin Kortüm, Max S. Topp, Leo Rasche

Blood (2023) 142 (Supplement 1): 3372.

https://doi.org/10.1182/blood-2023-188501

Published: 2023

Journal Articles

Real-World Analysis of Teclistamab in 115 RRMM Patients from Germany

Blood (2023) 142 (Supplement 1): 3329.

https://doi.org/10.1182/blood-2023-180032

Published: 2023

Journal Articles

Taste Abnormalities Emerging during Anti-Myeloma Therapies Including GPRC5D x CD3 Bispecific Antibody Talquetamab

Anna Fleischer, Magdalena Roll, Franziska Panther, Goetz Gelbrich, Franziska Reinhardt, Christine Riedhammer, Julia Mersi, Johannes M Waldschmidt, Hermann Einsele, K. Martin Kortüm, Imad Maatouk, Leo Rasche

Blood (2023) 142 (Supplement 1): 2403.

https://doi.org/10.1182/blood-2023-186663

Published: 2023

Journal Articles

Bone Marrow Plasma Cell Infiltration Is a Prognostic Factor for Response to AL Amyloidosis Therapy

Maximilian J Steinhardt, Vladimir Cejka, Caroline Morbach, Aikaterini Papagianni, Silvia Nerreter, Cornelia Vogt, Umair Munawar, Seungbin Han, Leo Rasche, Johannes M Waldschmidt, Claudia Sommer, Stefan Störk, Hermann Einsele, K. Martin Kortüm

Blood (2023) 142 (Supplement 1): 6753.

https://doi.org/10.1182/blood-2023-189326

Published: 2023

Journal Articles

Safety and Efficacy of Venetoclax Salvage Therapy in Relapsed/Refractory Multiple Myeloma with and without t(11;14)

Maximilian J Steinhardt, Max Bittrich, Xiang Zhou, Julia Noderer, Christine Riedhammer, Xianghui Xiao, Sophia Gawlas, Philipp Weis, Florian Eisele, Umair Munawar, Seungbin Han, Julia Mersi, Johannes M Waldschmidt, Hermann Einsele, Leo Rasche, K. Martin Kortüm

Blood (2023) 142 (Supplement 1): 6702.

https://doi.org/10.1182/blood-2023-189927

Published: 2023

Journal Articles

Secondary Genetic Events Impact the Expression of Key Immunotargets on the Surface of Multiple Myeloma Cells

Umair Munawar, Patrick Eiring, Cornelia Vogt, Larissa Haertle, Seungbin Han, Silvia Nerreter, Eva Teufel, Max Steinhardt, Xiang Zhou, Santiago Barrio, Hermann Einsele, Johannes M Waldschmidt, Leo Rasche, Markus Sauer, K. Martin Kortüm

Blood (2023) 142 (Supplement 1): 451.

https://doi.org/10.1182/blood-2023-180638

Published: 2023

Journal Articles

Prolonged Cytopenia Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Prospective Comprehensive Biomarker Study

Xiang Zhou, Vivien Wagner, Emilia Stanojkovska, Christine Riedhammer, Xianghui Xiao, Mara John, Lukas Scheller, Umair Munawar, Seungbin Han, Johannes M Waldschmidt, Max S. Topp, Johannes Duell, Hermann Einsele, Angela Riedel, Martin Kortüm, Leo Rasche

Blood (2023) 142 (Supplement 1): 95.

https://doi.org/10.1182/blood-2023-180534

Published: 2023

Journal Articles

The Impact of Treatment-Free Intervals on T-Cell Exhaustion and Clonotypic Diversity in Myeloma Patients Treated with BCMA Bispecific Antibodies

Florian Eisele, Nazia Afrin, Emilia Stanojkovska, Mara John, Moutaz Helal, Lars Grundheber, Philipp Weis, Christine Riedhammer, Sofie-Katrin Kadel, Max Steinhardt, Johannes Duell, Johannes M Waldschmidt, Hermann Einsele, Angela Riedel, K. Martin Kortüm, Leo Rasche

Blood (2023) 142 (Supplement 1): 1938.

https://doi.org/10.1182/blood-2023-189042

Published: 2023

Journal Articles

Intracytoplasmatic BCMA Point Mutation and Teclistamab Resistance: Genomic Assessment of a Multidrug-Resistant Multiple Myeloma Patient

Natalia Buenache Cuenda, Hipolito Nicolas Cuesta Hernández, Alicia Giménez Sánchez, Laura Carneros Blanco, Juan Manuel Rosa-Rosa, Yanira Ruiz-Heredia, Enrique Revilla, Seungbin Han, Umair Munawar, Inmaculada Rapado, Rosa Ayala, K. Martin Kortüm, Antonio Valeri, Santiago Barrio, Joaquin Martinez Lopez, Larissa Haertle

Blood (2023) 142 (Supplement 1): 1925.

https://doi.org/10.1182/blood-2023-184824

Published: 2023

Journal Articles

Euroflow-Based Ultrasensitive NGF for the Evaluation of Bone Marrow Minimal Residual Disease in Multiple Myeloma

Paula Tabares Gaviria, Katharina Schmiedgen, Jayabhuvaneshwari Dhanraj, Hüsniye Dagdeviren, Amy Wilnit, Maria Ulbrich, Bruno Paiva, K. Martin Kortüm, Leo Rasche, Hermann Einsele, Andreas Beilhack, Johannes M Waldschmidt

Blood (2023) 142 (Supplement 1): 3342.

https://doi.org/10.1182/blood-2023-189095

Published: 2023

Journal Articles

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

Janaki Manoja Vinnakota, Francesca Biavasco, Marius Schwabenland, Chintan Chhatbar, Rachael C Adams, Daniel Erny, Sandra Duquesne, Nadia El Khawanky, Henrike Salié, Dimitrios Athanassopoulos, Lukas Braun, Dominik Schmidt, Viktor Fetsch, Rebeka N. Javorniczky, Jenny N.H.G Ho, Reinhard Marks, Ralph Wäsch, Federico Simonetta, Geoffroy Andrieux, Dietmar Pfeifer, Gianni Monaco, Christian Capitini, Terry J. Fry, Thomas Blank, Bruce R Blazar, Eva-Maria Wagner Drouet, Matthias Theobald, Clemens Sommer, Matthias Stelljes, Christian Reicherts, Astrid Jeibmann, Jens Schittenhelm, Camelia-Maria Monoranu, Andreas Rosenwald, K. Martin Kortüm, Leo Rasche, Hermann Einsele, Philipp Tobias Meyer, Joachim Brumberg, Andreas Mackensen, Michael von Bergwelt-Baildon, Roland Coras, Nathalie L. Albert, Laura M. Bartos, Matthias Brendel, Adrien Holzgreve, Melanie Boerries, Crystal L. Mackall, Justus Duyster, Natalie Koehler, Felix Strübing, Bertram Bengsch, Marco Ruella, Marion Subklewe, Louisa von Baumgarten, Saar Gill, Marco Prinz, Robert Zeiser

Blood (2023) 142 (Supplement 1): 100.

https://doi.org/10.1182/blood-2023-184867

Published: 2023

Journal Articles

Differential CD38 Expression on Daratumumab-Naïve Vs. Resistant Multiple Myeloma - a Direct Stochastic Optical Reconstruction Microscopy ( d STORM) Analysis in 53 Patients

Maximilian J Steinhardt, Patrick Eiring, Cornelia Vogt, Umair Munawar, Seungbin Han, Larissa Haertle, Silvia Nerreter, Eva Teufel, Julia Mersi, Xiang Zhou, Michael Hudecek, Joaquin Martinez-Lopez, Johannes M Waldschmidt, Hermann Einsele, Leo Rasche, Markus Sauer, K. Martin Kortüm

Blood (2023) 142 (Supplement 1): 1992.

https://doi.org/10.1182/blood-2023-189741

Published: 2023

Journal Articles

Clinical and Diagnostic Challenges in Patients with Concomitant Plasma Cell Disorders and Myeloproliferative Neoplasms

Maximilian J Steinhardt, Thomas Bumm, Xiang Zhou, Umair Munawar, Seungbin Han, Julia Mersi, Hermann Einsele, Leo Rasche, K. Martin Kortüm, Johannes M Waldschmidt

Blood (2023) 142 (Supplement 1): 6771.

https://doi.org/10.1182/blood-2023-189528

Published: 2023

Journal Articles

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAF V600E -mutated multiple myeloma

Blood (2023) 141 (14): 1685–1690.

https://doi.org/10.1182/blood.2022017789

Published: 2023

Includes: Supplemental data

Journal Articles

Cereblon enhancer methylation and IMiD resistance in multiple myeloma

Blood (2021) 138 (18): 1721–1726.

https://doi.org/10.1182/blood.2020010452

Published: 2021

Includes: Supplemental data

Journal Articles

RAC1 Inhibitor EHT1864 and Venetoclax Overcome Midostaurin Resistance in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1277.

https://doi.org/10.1182/blood-2019-129762

Published: 2019

Journal Articles

Clonal Competition Models to Understand Progression and Resistance in Myeloma

Santiago Barrio, PhD, Larissa Haertle, PhD, Umair Munawar, MSc, Lucia Martin, Isabel Cuenca, MSc, Cornelia Vogt, MSc, Andoni Garitano-Trojaola, PhD, Matteo Claudio Da Via', MD, Miguel Gallardo, PhD, Thorsten Stuehmer, PhD, Hermann Einsele, MD, Leo Rasche, MD, Joaquin Martinez-Lopez, MD PhD, Martin Kortüm, MD

Blood (2019) 134 (Supplement_1): 1807.

https://doi.org/10.1182/blood-2019-130812

Published: 2019

NARROW

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis

Functional Characterization of GPRC5D alteration and Its Impact on Talquetamab Resistance in Relapsed/ Refractory Multiple Myeloma

Functional Imaging As a Key Diagnostic Tool in the Follow-up of RRMM Patients after CAR-T-Cell Therapy

Real-World Analysis of Teclistamab in 115 RRMM Patients from Germany

Taste Abnormalities Emerging during Anti-Myeloma Therapies Including GPRC5D x CD3 Bispecific Antibody Talquetamab

Bone Marrow Plasma Cell Infiltration Is a Prognostic Factor for Response to AL Amyloidosis Therapy

Safety and Efficacy of Venetoclax Salvage Therapy in Relapsed/Refractory Multiple Myeloma with and without t(11;14)

Secondary Genetic Events Impact the Expression of Key Immunotargets on the Surface of Multiple Myeloma Cells

Prolonged Cytopenia Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Prospective Comprehensive Biomarker Study

The Impact of Treatment-Free Intervals on T-Cell Exhaustion and Clonotypic Diversity in Myeloma Patients Treated with BCMA Bispecific Antibodies

Intracytoplasmatic BCMA Point Mutation and Teclistamab Resistance: Genomic Assessment of a Multidrug-Resistant Multiple Myeloma Patient

Euroflow-Based Ultrasensitive NGF for the Evaluation of Bone Marrow Minimal Residual Disease in Multiple Myeloma

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

Differential CD38 Expression on Daratumumab-Naïve Vs. Resistant Multiple Myeloma - a Direct Stochastic Optical Reconstruction Microscopy ( d STORM) Analysis in 53 Patients

Clinical and Diagnostic Challenges in Patients with Concomitant Plasma Cell Disorders and Myeloproliferative Neoplasms

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAF V600E -mutated multiple myeloma

Cereblon enhancer methylation and IMiD resistance in multiple myeloma

RAC1 Inhibitor EHT1864 and Venetoclax Overcome Midostaurin Resistance in Acute Myeloid Leukemia

Clonal Competition Models to Understand Progression and Resistance in Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only